Men are often told to “tough it out,” but prostate cancer tells a different story. High?risk disease is linked to higher rates of major depression and suicide over 10+ years—and emerging evidence shows preexisting depression may further worsen survival—underscoring the need for early, ongoing support. keep reading

A recent dialogue published in JAMA highlights emerging hope in the world of prostate cancer. From liquid biopsies to treat-resistant therapies and AI-powered diagnostics, this professional exchange underscores how science is steadily improving detection, care, and outcomes. keep reading

New tools like biomarker tests and 3T mpMRI are transforming how doctors evaluate a high PSA. Learn how these innovations reduce unnecessary prostate biopsies—saving patients from risk, stress, and costs—while delivering greater clarity in prostate cancer diagnosis. keep reading

On May 18, 2025 it was formally announced that former President Joe Biden had been diagnosed with prostate cancer that has spread to bone. Speaking for all of us at the Sperling Prostate Center, our hearts go out to President Biden and his family. How was he diagnosed? According to news reports... keep reading

Testosterone, or low T. No matter what you call it, it’s time to debunk the myth that testosterone therapy for men with low T increases prostate cancer risk. It all began over 80 years ago. “In 1941 Huggins and Hodges reported that marked reductions in T by castration or estrogen treatment caused metastatic [prostate cancer keep reading

Check out the name of this type of prostate imaging: microultrasonography. It’s a mouthful, and if you have trouble pronouncing it, you’re not alone. Let me break it down: Micro = very small. You may know words like micrometer or micromanage, same idea. Ultrasono = ultrasound. Graphy = graphics. Put it all together and it keep reading

Today’s multiparametric MRI (mpMRI) has revolutionized the prostate cancer (PCa) world. Thanks to its high resolution, 3-dimensional imaging done by a powerful 3 Tesla (3T) magnet, experienced radiologists are able to identify areas that are suspicious for clinically significant PCa (csPCa). This helps avoid unnecessary biopsies, but if a biopsy is indicated, the area can keep reading

How times and technology change! Take, for example, the shift from a tangible book like the Yellow Pages to a digital one. At one time, paper copies of the Yellow Pages business directory were delivered to virtually every household in America. This hefty local book was the ultimate resource for finding a business or service keep reading

Today’s multiparametric MRI (mpMRI) is better than ever. When a patient’s PSA blood test raises suspicion of prostate cancer (PCa), mpMRI determines if a targeted biopsy is needed. It does this by making significant lesions visible prior to an invasive biopsy. Significant means Gleason 3+4 or greater, also characterized as Grade Group 2 or greater. keep reading

A new paper on PSA screening for prostate cancer (PCa) begins by pointing out that screening reduces PCa deaths; however, PSA followed by immediate biopsy increases cases of low-risk patients who have overly aggressive treatments that leave them with impaired urinary or sexual function—up to 12 years or more![i] The authors propose more refined screening keep reading